• 1
    Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93 151.
  • 2
    Fritzler MJ & Andrade L. Antibodies to nonhistone antigens in systemic lupus erythematosus. In: LahitaRG, ed. Systemic lupus erythematosus. San Diego: Academic Press, 1999.
  • 3
    Mongey AB & Hess EV. The potential role of environmental agents in systemic lupus erythematosus and associated disorders. In: WallaceDJ, HahnBH, eds. Dubois' lupus erythematosus. Philadelphia: Lea and Febiger, 1993.
  • 4
    Burlingame RW & Rubin RL. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 1991; 88:680 90.
  • 5
    Griem P & Gleichmann E. Metal ion induced autoimmunity. Curr Opin Immunol 1995; 7:831 8.
  • 6
    Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298:1157 9.
  • 7
    Hultman P, Ganowiak K, Turley SJ, Pollard KM. Genetic susceptibility to silver-induced anti-fibrillarin autoantibodies in mice. Clin Immunol Immunopathol 1995; 77:291 7.
  • 8
    Hultman P, Bell LJ, Enestrom S, Pollard KM. Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in inbred, congenic, and intra-H-2 recombinant strains. Clin Immunol Immunopathol 1992; 65:98 109.
  • 9
    Speirs C, Fielder AH, Chapel H, Davey NJ, Batchelor JR. Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet 1989; 1:922 4.
  • 10
    Batchelor JR, Welsh KI, Tinoco RM et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980; 1:1107 9.
  • 11
    Robinson CJG, Balazs T, Egorov IK. Mercuric chloride-, gold sodium thiomalate-, and d-penicillamine-induced antinuclear antibodies in mice . Toxicol Appl Pharmacol 1996; 86:159 69.
  • 12
    Adams LE, Balakrishnan K, Roberts SM et al. Genetic, immunologic and biotransformation studies of patients on procainamide. Lupus 1993; 2:89 98.
  • 13
    Satoh M & Reeves WH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 1994; 180:2341 6.
  • 14
    Satoh M, Kumar A, Kanwar YS, Reeves WH. Antinuclear antibody production and immune complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA 1995; 92:10934 8.
  • 15
    Satoh M, Hamilton KJ, Ajmani AK et al. Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane. J Immunol 1996; 157:3200 6.
  • 16
    Satoh M, Shaheen VM, Kao PN et al. Autoantibodies define a family of proteins with conserved double-stranded RNA binding domains as well as DNA-binding activity. J Biol Chem 1999; 274:34598 604.
  • 17
    Elkon KB, Bonfa E, Brot N. Antiribosomal antibodies in systemic lupus erythematosus. Rheum Dis Clin North Am 1992; 18:377 90.
  • 18
    Hamilton KJ, Satoh M, Swartz J, Richards HB, Reeves WH. Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. Clin Immunol Immunopathol 1998; 86:271 9.
  • 19
    Anderson PN & Potter M. Induction of plasma cell tumours in BALB/c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature (Lond) 1969; 222:994 5.
  • 20
    Potter M & Wax JS. Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol 1981; 127:1591 5.
  • 21
    Wooley PH, Seibold JR, Whalen JD, Chapdelaine JM. Pristane-induced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease. Arthritis Rheum 1989; 32:1022 30.
  • 22
    Wooley PH. Immunogenetics of animal models of rheumatoid arthritis. In: HendersonB, EdwardsJCW, PettipherER, eds. Mechanisms and models in rheumatoid arthritis. London: Academic Press, 1995.
  • 23
    Potter M, Wax JS, Blankenhorn E. BALB/c subline differences in susceptibility to plasmacytoma induction. Curr Top Microbiol Immunol 1985; 122:234 41.
  • 24
    Labrador M, Alguero A, Diaz C et al. Antibodies against a novel nucleolar and cytoplasmic antigen (p105-p42) present in the sera of patients with a subset of rheumatoid arthritis (RA) with signs of scleroderma. Clin Exp Immunol 1998; 114:301 10.
  • 25
    Cohen PL & Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease . Annu Rev Immunol 1991; 9:243 69.
  • 26
    Bernard NF, Eisenberg RA, Cohen PL. H-2 linked Ir gene control of the T cell recognition of the Sm nuclear autoantigen and the aberrant response of autoimmune MRL/Mp-+/+ mice. J Immunol 1985; 134:3812 8.
  • 27
    Tan EM. Autoantibodies to nuclear antigens (ANA): their biology and medicine. Adv Immunol 1982; 33:167 240.
  • 28
    Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. IL-6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 1998; 188:985 90.
  • 29
    Deshmukh US, Lewis JE, Gaskin F et al. Immune responses to Ro60 and its peptides in mice. I. The nature of the immunogen and endogenous autoantigen determine the specificities of the induced autoantibodies. J Exp Med 1999; 189:531 40.